YmAbs Therapeutics (YMAB)
(Real Time Quote from BATS)
$12.89 USD
+0.04 (0.31%)
Updated May 23, 2024 11:06 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 81 - 100 ( 149 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Priority Review Voucher From DANYELZA FDA Approval Sold for $105M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Regional Agreements Inked For DANYELZA and Omburtamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA Receives Accelerated Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab Approval Appears Imminent; 3Q20 Financials; Raising PT to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lutetium-177 Labeled Omburtamab Cleared to Advance Into Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SIOP Data Reinforces Efficacy Profiles of Lead Candidates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Y-mAbs Now Eligible for Four Priority Review Vouchers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Refusal to File Letter a Minor Delay, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab BLA Still Intact, But Omburt Suffers Slight Setback
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D